In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinetobacter baumannii

Chemotherapy

Volumn 49, Issue 1-2, 2003, Pages 24-26

  Fernández Cuenca, Felipe ^a   Martínez Martínez, Luis ^a,b   Pascual, Alvaro ^a,b   Perea, Evelio J ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Acinetobacter baumannii; Antimicrobial agent combinations; Azithromycin; In vitro activity

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; AMIKACIN; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFTAZIDIME; CIPROFLOXACIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SPECIES SPECIFICITY; STAPHYLOCOCCUS AUREUS;

EID: 0037262561     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069774     Document Type: Article

References (7)

1. Bergogne-Bérézin E, Towner KJ: Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-165.
2. Martínez-Martínez L, Rodríguez G, Pascual A, Suárez AI, Perea EJ: In vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1995;38:1107-1108.
3. Appleman MD, Belzberg H, Citron DM, Heseltine PN, Yellin AE, Murray J, Berne TV: In vitro activities of non-traditional antimicrobials against multiresistant Acinetobacter baumanniistrains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother 2000;44:1035-1040.
4. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacterials that Grow Aerobically. Approved Standard M7-A5. Wayne, NCCLS, 2000.
5. Eliopoulos GM, Moellinger RC Jr: Antimicrobial combinations; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 6. Baltimore, Williams & Wilkins, 1996, pp 330-396.
6. Kawamura K, Iinuma Y, Hasegawa T, Horii T, Yamashino T, Ohta M: Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 2000;44:2869-2872.
7. Kobayashi H: Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995;99(suppl 6A):26-30.